Compare AVAH & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAH | MPLT |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2021 | N/A |
| Metric | AVAH | MPLT |
|---|---|---|
| Price | $9.49 | $36.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $9.75 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 2.3M | 563.2K |
| Earning Date | 05-14-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1850.00 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $2,433,199,000.00 | N/A |
| Revenue This Year | $7.31 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $47.79 | ★ N/A |
| Revenue Growth | ★ 20.19 | N/A |
| 52 Week Low | $3.73 | $12.24 |
| 52 Week High | $10.32 | $40.43 |
| Indicator | AVAH | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 59.37 | 54.74 |
| Support Level | $8.80 | $26.20 |
| Resistance Level | $9.86 | $40.43 |
| Average True Range (ATR) | 0.42 | 2.75 |
| MACD | -0.11 | -0.46 |
| Stochastic Oscillator | 49.07 | 35.78 |
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.